Stock Surge: Akebia Therapeutics Inc. (AKBA) Closes at 0.91, Marking a -3.19 Increase/Decrease

Seeking to outpace the market, investors engage in the art of selecting individual stocks. The right picks can play a pivotal role in boosting your wealth.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

In the latest session, Akebia Therapeutics Inc. (NASDAQ: AKBA) closed at $0.91 down -3.19% from its previous closing price of $0.94. In other words, the price has decreased by -$3.19 from its previous closing price. On the day, 3.67 million shares were traded. AKBA stock price reached its highest trading level at $0.96 during the session, while it also had its lowest trading level at $0.9025.

Ratios:

For a deeper understanding of Akebia Therapeutics Inc.’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.31 and its Current Ratio is at 1.70.

On August 28, 2023, H.C. Wainwright Upgraded its rating to Buy which previously was Neutral but kept the price unchanged to $3.75.

Piper Sandler Upgraded its Neutral to Overweight on May 31, 2023, whereas the target price for the stock was revised from $2 to $4.

Insider Transactions:

Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on May 13 ’24 when Dahan Michel sold 34,840 shares for $1.26 per share. The transaction valued at 43,898 led to the insider holds 672,092 shares of the business.

Hadas Nicole R. sold 12,016 shares of AKBA for $15,140 on May 13 ’24. The SVP, Chief Legal Officer now owns 651,243 shares after completing the transaction at $1.26 per share. On Feb 29 ’24, another insider, Butler John P., who serves as the CEO and President of the company, sold 46,570 shares for $1.58 each. As a result, the insider received 73,581 and left with 2,044,580 shares of the company.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, AKBA now has a Market Capitalization of 190732368 and an Enterprise Value of 247115696. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.02. Its current Enterprise Value per Revenue stands at 1.32 whereas that against EBITDA is 62.309.

Stock Price History:

Over the past 52 weeks, AKBA has reached a high of $2.48, while it has fallen to a 52-week low of $0.78. The 50-Day Moving Average of the stock is -25.99%, while the 200-Day Moving Average is calculated to be -29.18%.

Shares Statistics:

For the past three months, AKBA has traded an average of 4.62M shares per day and 2280830 over the past ten days. A total of 194.58M shares are outstanding, with a floating share count of 191.87M. Insiders hold about 8.46% of the company’s shares, while institutions hold 20.89% stake in the company. Shares short for AKBA as of 1715731200 were 11698707 with a Short Ratio of 2.85, compared to 1713139200 on 13689136. Therefore, it implies a Short% of Shares Outstanding of 11698707 and a Short% of Float of 5.6399997.

Earnings Estimates

At present, 3.0 analysts are actively evaluating the performance of Akebia Therapeutics Inc. (AKBA) in the stock market.On average, analysts expect EPS of -$0.05 for the current quarter, with a high estimate of -$0.03 and a low estimate of -$0.08, while EPS last year was -$0.06. The consensus estimate for the next quarter is -$0.08, with high estimates of -$0.05 and low estimates of -$0.11.

Analysts are recommending an EPS of between -$0.2 and -$0.37 for the fiscal current year, implying an average EPS of -$0.3. EPS for the following year is -$0.33, with 3.0 analysts recommending between $0.08 and -$0.58.

Revenue Estimates

A total of 3 analysts believe the company’s revenue will be $49.45M this quarter.It ranges from a high estimate of $54M to a low estimate of $45.6M. As of the current estimate, Akebia Therapeutics Inc.’s year-ago sales were $56.38MFor the next quarter, 3 analysts are estimating revenue of $44.71M. There is a high estimate of $46.28M for the next quarter, whereas the lowest estimate is $41.9M.

A total of 2 analysts have provided revenue estimates for AKBA’s current fiscal year. The highest revenue estimate was $180.47M, while the lowest revenue estimate was $164.6M, resulting in an average revenue estimate of $172.53M. In the same quarter a year ago, actual revenue was $194.62MBased on 3 analysts’ estimates, the company’s revenue will be $159.38M in the next fiscal year. The high estimate is $184M and the low estimate is $125.9M.

Most Popular